FTV — Fortive Corporation

The tape is unambiguously negative as of 2026-09-13: FTV was down 3.95% on the week, 11.13% on the month and 9.06% over three months, trading 5.94-9.13% below its 20-, 50- and 200-day moving averages with RSI(14) at 29.82. That is a punitive reaction to a quarter that beat on both lines and came with a guidance raise, which means the market is discounting the guidance rather than the print - EMEA softness, gross-margin commentary, and a debt balance that jumped from $2.31B long-term (2025-12-31) to $3.51B (2026-07-03) are doing the damage. Sell-side consensus is a cautious 'Hold' (11 buy / 17 hold / 2 sell, per the research brief's tally) with a $64.67 average target, so the Street is not bearish on value - it is simply unwilling to defend the price while execution is questioned.

The single most important fact in this dataset is the step-down in reported revenue at Q3 2025 ($1,027.1M) from Q2 2025 ($1,518.8M) - that is the Precision Technologies divestiture, not demand destruction, and it makes every trailing YoY comparison on this name close to meaningless. Post-divestiture revenue has been stable-to-growing sequentially: 1,027.1 -> 1,122.5 -> 1,069.4 -> 1,096.8 across Q3 2025 through Q2 2026, with management reporting +6.7% core growth in Q2 2026 and ~4% full-year core. Gross margin inflected UP with the mix shift, from 59.0-60.3% across the 2023-2024 quarters to 63.2-63.4% in each of the last four quarters (Q2 2026: 63.4%) - the 'gross margin pressure' narrative in the news flow is not visible in the reported numbers; the level is flat to slightly up. Operating margin is noisier: 15.5% (Q3 2025, the divestiture-loss quarter), 20.1% (Q4 2025), 17.9% (Q1 2026), 19.1% (Q2 2026), and the +181bps YoY comparison versus Q2 2025's 17.3% flatters a business whose pre- and post-divestiture mixes differ. Earnings quality is the real wrinkle: TTM GAAP EPS is ~$1.70 (FMP shows $1.757) versus ~$2.22 for the prior TTM, dragged by Q3 2025 net income of just $55.0M / $0.17 EPS. But TTM free cash flow of $954.9M is 179% of TTM net income and the accruals ratio is a healthy -1.11%, confirming the profit decline was mostly non-cash. Cash generation is nonetheless shrinking in absolute terms - TTM FCF of $954.9M versus $1,400.3M for the prior four quarters, a 32% decline - though a large chunk of that was cash the divested Precision business used to generate. Net read: this is an inflecting, not structurally deteriorating, story, and the next clean YoY comparison arrives with Q3 2026.

Trailing metrics look expensive, forward metrics look cheap, and the forward numbers deserve more weight. As of 2026-09-13, P/E TTM was 31.8x versus a five-year average of 27.1x, and P/S was 3.83x versus a 3.31x five-year average - both about 17% above history, which is exactly what drives the deterministic overlay's 'Rich vs. its own history' tag. But the trailing P/E denominator is polluted: TTM EPS of $1.757 includes a $0.17 EPS quarter (Q3 2025) loaded with divestiture-related charges. Against the company's own raised FY2026 adjusted EPS guidance of $2.95-$3.05 and the $3.017 FY2027 consensus, the stock trades at roughly 18.1-18.5x forward earnings - a ~33% discount to its own five-year average multiple and below most diversified industrial peers. PEG of -1.39 is unusable (negative trailing growth on divestiture comps). On EV/EBITDA (~18.6x) and P/B (2.75x) it is not obviously cheap; on forward earnings it is. Verdict as of 2026-09-13: fairly valued to modestly cheap if ~6% core growth persists, expensive if it does not.

The gap between the 31.8x trailing P/E and the ~18.2x forward P/E is the whole story. The market is not paying 31.8x earnings - it is paying ~18x 2026 guidance and effectively signalling it does not fully believe the guidance or that the mix improvement sticks. Concretely, as of 2026-09-13 at $54.69 you are buying FY26E adjusted EPS of ~$3.00 at 18.2x with a just-raised dividend ($0.07/quarter, +16.7%). If Q3 2026 (late Oct/early Nov) prints core growth of 5-7% and adjusted EPS of $0.75-0.80, the multiple is too low and $60-65 is an easy path. If core growth slips toward 2-3% as EMEA softens, the multiple is roughly right and $47-50 is the realistic band. The fact that the stock fell 11% on a beat tells you the market is already leaning toward the second scenario - which is where either the opportunity or the value trap sits.

As of 2026-09-13, RSI(14) stood at 29.82 - technically oversold - with the price at $54.69 sitting 6.37% below its 20-day, 9.13% below its 50-day and 5.94% below its 200-day moving average, and a previous close of $54.51. This is a sharp short-term breakdown inside an otherwise range-bound six months (6-month return still +0.77%, versus -3.95% on the week and -11.13% on the month), placing the stock ~15% below its $64.56 52-week high and ~16% above its $47.31 low. Backing out implied averages from those percentages puts the 20-day near $58.4, the 50-day near $60.2 and the 200-day near $58.1 - i.e. price has fallen through a cluster rather than a cleanly stacked downtrend, and the 50-day is still above the 200-day. Implication: an oversold bounce is a reasonable near-term base case, but this is not a confirmed trend reversal. Staggered entries near $52-54 with a hard line below the $47.31 low, and no trend-change assumption until the 20-day (~$58) is reclaimed, is the honest way to play this tape.

• Rate sensitivity and funding costs: FTV's beta is 0.973 but it trades with long-duration industrials, and with roughly $3.1B of net debt (about 3x EBITDA) a higher-for-longer rate environment raises the bar for the debt-funded buybacks that have supported EPS (long-term debt rose $1.2B in the two quarters to 2026-07-03).
• EMEA softness and FX: management flagged European regional weakness in the Q2 2026 update; with roughly half of revenue international, a slow European industrial recovery is a persistent 1-2pt drag on core growth and a recurring source of guidance haircuts.
• Structural tailwinds in data center expansion, defense and healthcare workflow automation - the end markets behind Fluke and Industrial Scientific demand and ASP's hospital sterilization consumables. About 50% of revenue is now recurring software/subscription, a genuine margin and visibility buffer against input-cost inflation.
• Tariffs and hardware input costs: Fortive still ships substantial physical instrumentation, so component costs and trade policy remain a gross-margin swing factor even at a 63% gross margin.
• Sector rotation away from high-multiple industrial compounders toward cheaper, higher-ROIC names - FTV's 7.4% ROIC makes it a structurally vulnerable candidate for that rotation regardless of its end-market exposure.

• Morgan Stanley 14th Annual Laguna Conference on September 15, 2026 - the first management update since the raised FY26 guide; watch for any change in the ~4% core growth framing or commentary on EMEA.
• Q3 2026 earnings (late October / early November 2026) - the first clean YoY revenue comparison after the Precision Technologies divestiture; a 5-7% core print with adjusted EPS of $0.75+ would validate the $2.95-$3.05 guide and likely re-rate the multiple.
• Continued bolt-on M&A and buyback pace (UV Smart majority stake closed in Q2 2026; ~$2B of repurchases over the trailing four quarters) - further repurchases at ~18x forward earnings would be accretive.
• The 16.7% dividend increase to $0.07/quarter, going ex-dividend ahead of the September 25, 2026 payment date - a small but real management signal on cash-generation confidence.
• Any further portfolio action - Fortive has reshaped its portfolio repeatedly; another higher-margin acquisition or divestiture would reset the earnings base and the comp structure again.

• Leverage creep: long-term debt rose from $2.31B at 2025-12-31 to $3.51B at 2026-07-03 while stockholders' equity fell from $6.45B to $6.06B, leaving roughly $3.14B of net debt (~3x EBITDA) and less room for error if core growth slows.
• Mediocre returns on capital: ROIC of 7.4% and ROE of 9.0% are below what an ~18x forward P/E implies and below most diversified industrial peers - part of the weak growth score is a real capital-efficiency problem, not just a divestiture artifact.
• Free cash flow compression: TTM FCF of $954.9M is 32% below the prior TTM's $1,400.3M; even allowing for the divestiture, the absolute cash base funding the dividend and buybacks is materially smaller.
• Growth credibility: the market sold the stock down 11% in a month despite a beat and a raise; if Q3 2026 core growth decelerates toward 2-3% as EMEA softens, ~18x forward is not a floor.
• Portfolio and accounting noise: three years of divestiture restatements plus a $0.17 EPS quarter make trailing comparisons and even consensus estimates unusually unreliable, so modelling off TTM figures carries real error risk.

Honest read: Fortive is a decent, defensible business - 63% gross margin, ~50% recurring revenue, +6.7% Q2 core growth, freshly raised guidance - but it is not cheap by accident. ROIC of 7.4%, ~3x net leverage, a 32% TTM free-cash-flow decline and two years of divestiture noise are the price of admission, and at $54.69 you are paying ~18x forward earnings for a mid-single-digit grower with a rising debt load. That is not a bargain, and the market's sell-off on a beat is a fair signal that it agrees. I would want either a price in the high-$40s/low-$50s or one clean quarter of 5%+ core growth (Q3 2026, late October) before treating this as a buy - the mandatory band/valuation mapping below also pushes the formal lean to Bearish, which is directionally consistent with that caution.

I applied a 20x multiple to my FY2027E adjusted EPS of $3.05 - a ~5% step-up from the raised FY2026 guidance midpoint of $3.00 and slightly above the $3.017 consensus - a discount to Fortive's 27.1x five-year average and to diversified industrial peers, justified by 7.4% ROIC and ~3x net leverage but supported by 6%+ core growth and a ~50% recurring-revenue mix. Cross-checks: 18x EV/EBITDA on ~$1.05B of EBITDA implies ~$52, and a 5.5% FCF yield on $954.9M of TTM free cash flow implies ~$57.5, so I weighted 60% to the earnings approach and 20% to each cross-check, landing at ~$61 as of 2026-09-13.